

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Wardlaw et al.

) Group Art Unit: 2863
) Examiner: A. Bhat
)

Title: APPARATUS FOR PROVIDING
QUALITY CONTROL IN AN
INSTRUMENT FOR MEDICAL
ANALYSIS

)
)
)
)
)
)
)

Serial No.: 10/733,542

)
)
)

Filed: December 11, 2003

) Our Docket No. 5169-0011-1-1

Springfield, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant(s) submits herewith Form PTO-1449 identifying patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.


The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

04/15/2005 BABRAHA1 00000034 10733542

02 FC:1806

180.00 OP

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on April 12, 2005 with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Kim M. Hume

Application Serial No.: 10/733,542
Docket No. 5169-0011-1-1

Under 37 CFR 1.97 (b)

☐ This Information Disclosure Statement is being filed within three months of the filing date of the application, or the date of entry into the national stage of an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Under 37 CFR 1.97 (c)

☒ This Information Disclosure Statement is being filed *after* three months of the filing date of this national application, or the date of entry into the national stage as set forth in §1.491 in an international application, or after the mailing date of the first Office Action on the merits, whichever event occurred last, but *before* the mailing date of either a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

☒ A certification as specified in 37 CFR 1.97(e) is set forth below.
Fee as set forth in 37 CFR 1.17(p) (\$180.00).

Under 37 CFR 1.97(d)

☐ This Information Disclosure Statement is being filed *after* a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. Applicant hereby petitions for the consideration of this Information Disclosure Statement, 37 CFR 1.97(d)(ii). A certification as specified in 37 CFR 1.97(e) is set forth below.

☐ Fee as set forth in 37 CFR 1.17(p) (\$180.00)

CERTIFICATION (37 CFR 1.97(e))


☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. A copy of the relevant search report is enclosed herewith.

☒ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this Statement.

Application Serial No.: 10/733,542
Docket No. 5169-0011-1-1

Applicants respectfully request that any deficiencies in the fees be charged to Deposit
Order Account No. 50-3381.

Respectfully submitted,

By: 
Richard D. Getz
Registration No. 36,147
O'Shea, Getz & Kosakowski, P.C.
1500 Main Street, Suite 912
Springfield, Massachusetts 01115
413-731-3100

FORM PTO-1449
(Rev. 5/92)O'SHEA, GETZ & KOSAKOWSKI, P.C.
1500 Main Street, Suite 912
Springfield, MA 01115
Telephone: (413) 731-3100ATTORNEY DOCKET NO.
5169-0011-1-1


APPLICANT: Wardlaw et al.

FILING DATE: December 11, 2003

SERIAL NO. 10/733,542

GROUP: 2863

EXAMINER: A. Bha

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	6,512,986	1/28/2003	Harmon	19	00	12/30/2000
	B	6,856,928	2/15/2005	Harmon	19	00	12/17/2002
	C						
	D						
	E						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	F						
	G						
	H						
	I						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL		
	J	Charlene Marietti "Golden Labs", Healthcare Infomatics Online, August 1998
	K	"Medical Automation Systems Announces Vendor-Independent-Point-of-Care Data Management Position", Medical Automation Systems, Inc., Charlottesville, VA USA 1/25/2001
	L	Robin A. Felder, Ph.D. "The Distributed Laboratory: Point-of-Care Services with Core Laboratory Management", The American Association for Clinical Chemistry, 1999
	M	"LifeScan Announces Removal And Replacement of Certain SURESTEP® Consumer Blood Glucose Meters", Johnson and Johnson 6/4/1998
	N	
	O	

EXAMINER

DATE CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.